Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cyt...

    2025-11-01

    Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

    Executive Summary. Y-27632 dihydrochloride (SKU: A3008) is a potent and selective small-molecule inhibitor of Rho-associated protein kinases, ROCK1 and ROCK2, with an IC50 of ~140 nM for ROCK1 and a Ki of 300 nM for ROCK2, demonstrating >200-fold selectivity over related kinases (ApexBio, product page). By inhibiting ROCK signaling, Y-27632 suppresses Rho-mediated stress fiber formation, modulates cell cycle progression, and impairs cytokinesis (ApexBio; Di Marzo et al., 2025). The compound is widely used to enhance stem cell viability, inhibit tumor invasion, and dissect cytoskeletal mechanisms. Solubility is high in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), and water (≥52.9 mg/mL) at 37°C. Benchmark studies confirm its reproducibility across cell types and mouse models. This dossier critically reviews Y-27632’s mechanism, benchmarks, and integration, contrasting its applications with alternative ROCK inhibitors (see here for stem cell niche engineering).

    Biological Rationale

    Rho-associated protein kinases (ROCK1 and ROCK2) are central effectors of the RhoA GTPase pathway. These kinases regulate actin cytoskeleton dynamics, cell shape, motility, and division. Dysregulation of ROCK signaling is implicated in cancer, fibrosis, and neurodegeneration (Di Marzo et al., 2025). Inhibition of ROCK kinases disrupts stress fiber assembly and alters cell-cycle transitions, providing a strategy to study cytoskeletal remodeling and tumor metastasis. Y-27632 dihydrochloride offers high selectivity for ROCK1/2, enabling precise modulation of downstream Rho/ROCK signaling. Its application extends to studies of epithelial barrier function, where cytoskeletal integrity underlies transepithelial resistance and permeability. The compound is also used to improve stem cell viability, as ROCK inhibition reduces dissociation-induced apoptosis in pluripotent stem cell cultures (reviewed here).

    Mechanism of Action of Y-27632 dihydrochloride

    Y-27632 dihydrochloride specifically targets the ATP-binding (catalytic) domains of ROCK1 and ROCK2. It competitively inhibits kinase activity, blocking phosphorylation of downstream effectors such as myosin light chain (MLC), LIM kinase, and cofilin. This inhibition prevents Rho-mediated assembly of actin stress fibers and focal adhesions. Quantitatively, the compound demonstrates an IC50 of ~140 nM for ROCK1 and a Ki of 300 nM for ROCK2, with >200-fold selectivity over kinases such as PKC, PKA, MLCK, and PAK (ApexBio). Y-27632 also impairs cell cycle progression from G1 to S phase and suppresses cytokinesis by interfering with contractile ring formation. The resulting phenotypes include decreased cellular contractility, rounded cell morphology, reduced migration, and increased survival in dissociated stem cells. Notably, Y-27632 does not inhibit unrelated kinases at research-relevant concentrations, minimizing off-target effects (see mechanism details).

    Evidence & Benchmarks

    • Y-27632 dihydrochloride inhibits ROCK1/2 with an IC50 of 140 nM (ROCK1) and a Ki of 300 nM (ROCK2) under in vitro kinase assay conditions (ApexBio datasheet, product page).
    • Exhibits >200-fold selectivity against PKC, PKA, MLCK, and PAK as measured by kinase panel screening (ApexBio, product page).
    • Reduces prostatic smooth muscle cell proliferation in vitro in a dose-dependent manner (see Table 2, Di Marzo et al., 2025).
    • Suppresses tumor invasion and metastasis in mouse models, with significant reduction in pathological structures at 10 mg/kg, i.p. (see Figure 4, Di Marzo et al., 2025).
    • Enhances survival of human pluripotent stem cells post-dissociation, reducing apoptosis by over 50% in feeder-free culture (protocol review).
    • Solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 37°C (ApexBio, product page).

    Applications, Limits & Misconceptions

    Y-27632 dihydrochloride is used in multiple research domains:

    • Cytoskeletal studies: Dissects actin dynamics by inhibiting stress fiber formation (compare strategic guidance).
    • Stem cell biology: Enhances survival and cloning efficiency of human ES and iPS cells.
    • Cancer research: Reduces invasion, metastasis, and proliferation in cell and animal models.
    • Barrier function: Modulates tight junctions and transepithelial resistance in organoids (Di Marzo et al., 2025).

    Y-27632’s high selectivity and cell-permeability make it a benchmark tool for Rho/ROCK pathway interrogation. However, its inhibition is reversible, and effects may depend on cell context and timing.

    Common Pitfalls or Misconceptions

    • Not a pan-kinase inhibitor: Y-27632 does not inhibit PKC, PKA, or MLCK at standard concentrations.
    • Not effective in all cell types: Some primary cells or non-mammalian models may not respond as expected.
    • Not suitable for chronic systemic administration: Long-term in vivo use may lead to compensatory pathway activation.
    • Solubility requires temperature optimization: Pre-warming or sonication is necessary for high-concentration stocks.
    • Does not directly affect eCBome: ROCK inhibitors do not modulate endocannabinoidome signaling like URB 597 or JZL 184 (cf. Di Marzo et al., 2025).

    Workflow Integration & Parameters

    To prepare Y-27632 dihydrochloride for cell culture, dissolve in DMSO (≥111.2 mg/mL) or water (≥52.9 mg/mL) at 37°C or use an ultrasonic bath to enhance solubility. Stock solutions should be stored desiccated below -20°C for several months; avoid repeated freeze-thaw cycles. Working concentrations typically range from 1–50 μM depending on application. For stem cell passaging, 10 μM is standard. For cancer and cytoskeletal assays, titrate to optimize for minimal toxicity and maximal effect. Always include vehicle controls (DMSO or water) in parallel experiments. For further practical tips and protocol optimization, see "Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibition for Advanced Cytoskeletal Research" – this article extends prior summaries by clarifying storage, solubility, and cell-type specific optimization.

    Conclusion & Outlook

    Y-27632 dihydrochloride (A3008) is a gold-standard tool for selective inhibition of ROCK1 and ROCK2, enabling precise modulation of cytoskeletal organization, cell proliferation, and tumor invasion. Its reproducible selectivity, robust solubility, and broad utility underpin its adoption in stem cell research, cancer models, and organoid systems. For comprehensive protocol guidance and critical discussion of its unique advantages, consult the manufacturer’s product page. Future research will further delineate its roles in tissue engineering and regenerative medicine, particularly as combination strategies with eCBome modulators or other pathway-specific agents are developed.